abstract |
The present invention provides novel prostate cell surface antigens and monoclonal antibodies to prostate stem cell antigens, methods of detection / diagnosis and treatment. Widely overexpressed in all stages of prostate cancer, referred to as prostate stem cell antigen (PSCA), including a high degree of neoplasia in the prostate epithelium (PIN), androgen-dependent and androgen-independent prostate tumors A novel prostate cell surface antigen. PSCA-specific monoclonal and polyclonal antibodies, as well as immunotherapy and other therapeutic methods for the treatment of prostate cancer. [Selection] Figure 1 |